A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita (VAPAUS)

NCT05180708 PHASE3 COMPLETED

This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.

Details

Lead sponsor	Palvella Therapeutics, Inc.
Phase	PHASE3
Status	COMPLETED
Enrolment	87
Start date	Mon Nov 29 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jun 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pachyonychia Congenita

Interventions

• QTORIN 3.9% rapamycin anhydrous gel
• Vehicle

Countries

United Kingdom, United States